The results of our genome-wide ChIP-Seq study suggest that the extent of RAD54-BLM–mediated chromatin remodeling is one of the key factors that causes chemoresistance to drugs used in colon cancer therapy. This evidence concerns the gene ATRX and malignant colon neoplasm.